- Protext Mobility, Inc. (OTC: TXTM) Ignites Next Phase of Growth with Investor Relations Presentation Initiative — Setting the Stage for a New Era of Transparency and Acceleration
- MicrobiotiX Receives IND Approval for Novel Bacteriophage Drug MP101
- MapLight Therapeutics Announces Pricing of Initial Public Offering
- Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
- Rentschler Biopharma Inc. named Manufacturer of the Year for Central Massachusetts
- Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results
- Kemira Water Index Discussed During Nationwide Media Tour with YourUpdateTV
- Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million
- Eleva advances CPV-104 into Phase 1b clinical testing in patients with C3G, following the successful completion of single ascending dose evaluation in healthy volunteers
- Anresco Laboratories and NJ Labs Unite to Form Nationwide Testing Network Built on Trusted, Proven Expertise
